Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•AuntMinnie
Adult-Trained Radiology AI Models Struggle in Pediatric Imaging
Adult-trained radiology AI models often underperform when applied to pediatric imaging data, according to a systematic review.
•AuntMinnie
AI Analyzes Chest CTs to Predict Cardiac Events Risk
A deep learning model can analyze routine chest CTs to predict major adverse cardiac event risk, outperforming traditional methods.
•AuntMinnie
AI Model Synthesizes Early-Stage PDAC CTs for Improved Detection
Researchers created AI models to generate synthetic early-stage PDAC CT scans, boosting early tumor detection sensitivity.